| Date | Time | Source | Headline | Symbol | Company |
| 07/11/2024 | 12:21PM | iHub Newswire | FeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing | | |
| 01/12/2010 | 6:24PM | Dow Jones News | FDA Warns Bayer, Eli Lilly For Misleading Drug Ads | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 01/11/2010 | 7:00PM | PR Newswire (US) | Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 01/04/2010 | 4:15PM | PR Newswire (US) | Amylin Pharmaceuticals to Present at J.P. Morgan Healthcare Conference | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 12/30/2009 | 7:49PM | Dow Jones News | CORRECT: Novo Nordisk Expects FDA Feedback Liraglutide In Weeks | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 12/30/2009 | 12:12PM | Dow Jones News | UPDATE: Novo Nordisk Expects FDA Feedback Liraglutide In Weeks | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 12/15/2009 | 4:12PM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 12/15/2009 | 8:15AM | Business Wire | Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA® in DURATION-5 Study | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 12/15/2009 | 8:00AM | PR Newswire (US) | Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 12/09/2009 | 1:35PM | Dow Jones News | Genzyme Adds Director As Major Investor Pushes For Change | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 12/08/2009 | 4:15PM | PR Newswire (US) | Amylin Pharmaceuticals to Present at the 2009 Deutsche Bank Biotech Boston Confab | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 12/02/2009 | 7:37AM | Dow Jones News | 3rd UPDATE: Roche Says Diabetes Drug Better Than Merck Januvia | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 12/02/2009 | 5:24AM | Dow Jones News | 2nd UPDATE:Roche Says Diabetes Drug Better Than Merck Januvia | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 11/27/2009 | 7:27AM | Marketwired | The Fortune Financial Undertakes Review of Stocks in the Healthcare and Services Sectors | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 11/16/2009 | 6:58AM | Marketwired | TheFortuneFinancial.com Free Market Research on FNFG, ILMN, JDSU, AMLN, ISIL and BRCD | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 11/05/2009 | 4:15PM | PR Newswire (US) | Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference | NASDAQ:AMLN | |
| 11/05/2009 | 5:32AM | Marketwired | BenchmarkJournal.com Receives Analysis on CYOU, ESLR, DRYS, ETFC, AMLN and COMS | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 11/03/2009 | 9:31AM | PR Newswire (US) | Critical Alerts for ConocoPhillips, US Bancorp, CVS Caremark, Amylin, and Newell Rubbermaid Released by Seven Summits Research | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 11/02/2009 | 5:02PM | Dow Jones News | UPDATE:FDA Approves New Byetta Label Amid Renal-Failure Reports | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 11/02/2009 | 5:00PM | Dow Jones News | CORRECT:=FDA Approves New Byetta Label Amid Renal-Failure Reports | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 11/02/2009 | 4:48PM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 11/02/2009 | 4:37PM | DPA AFX Nachrichten | ROUNDUP/Aktien New York Schluss: Schwankende Sitzung endet mit Erholung | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 11/02/2009 | 3:30PM | PR Newswire (US) | Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 11/02/2009 | 3:20PM | Dow Jones News | FDA Approves New Byetta Label Amid Renal-Failure Reports | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 11/02/2009 | 6:07AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 11/01/2009 | 6:30PM | PR Newswire (US) | Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity | NASDAQ:AMLN | |
| 10/30/2009 | 8:16PM | PR Newswire (US) | BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes | NASDAQ:AMLN | |
| 10/29/2009 | 8:34AM | Dow Jones News | UPDATE: Roche's New Diabetes Drug Works Better Than Byetta | NASDAQ:AMLN | Amylin Pharmaceuticals Inc. |
| 10/29/2009 | 5:02AM | Dow Jones News | Roche: New Diabetes Drug Works Better Than Byetta - Study | NASDAQ:AMLN | Amylin Pharmaceuticals Inc. |
| 10/27/2009 | 6:50AM | Marketwired | MWW, VRTX, BRCD, TIBX, AMLN and BMRN Free Research report on BenchmarkJournal.com | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |